A real-world pilot study assessing treatment satisfaction with avanafil in patients with erectile dysfunction

Ping-Ju Tsai,Shih-Ya Hung,Tsung-Hsi Lee,Bang-Ping Jiann

DOI: https://doi.org/10.1093/sexmed/qfae001

2024-02-01

Sexual Medicine

Abstract:Abstract Background Avanafil is a second-generation phosphodiesterase type 5 (PDE5) inhibitor, and offers a rapid onset of action (15 minutes). Its real-world data, including treatment satisfaction, are still lacking. Aim The study sought to investigate the treatment outcomes of avanafil and the factors impacting treatment satisfaction in a real-world setting. Methods Between November 2021 and February 2023, erectile dysfunction (ED) patients prescribed avanafil were consecutively enrolled in this phase 4, open-label, cross-sectional, observational study. At each follow-up visit (4-week intervals), participants completed a questionnaire for assessing the use and treatment-emergent adverse events of avanafil, ED severity, and treatment satisfaction. Outcomes The outcome measures included the Sexual Health Inventory for Men (SHIM), and Erectile Dysfunction Inventory of Treatment Satisfaction. Results Among 234 patients enrolled, 112 (47.9%) patients had follow-up visits and answered the questionnaire. Treatment with avanafil significantly improved the mean SHIM total score from 10.2 ± 5.6 at baseline to 17.5 ± 6.2 (P < .001). Of the patients treated with avanafil, 71.4% (n = 80 of 112) reported a >4-point improvement in the SHIM total score, and 33.1% (n = 37 of 112) reported normal erectile function. The proportion of patients satisfied with avanafil treatment (defined as Erectile Dysfunction Inventory of Treatment Satisfaction index score ≥60) was 87.5%. Several physical factors (younger age, lower waist circumference, and lower level of low-density lipoprotein), and sexual function factors (shorter duration of ED, higher SHIM total score at baseline, PDE5 inhibitor treatment naive, and acquired premature ejaculation) tended to contribute to satisfaction with avanafil treatment. Treatment-emergent adverse events occurred in 41.1% of patients, and all were mild in severity. Clinical Implications This study identifies the factors associated with treatment satisfaction of avanafil, which may ultimately lead to better treatment outcomes. Strengths and Limitations This is the first study to provide real-world evidence of avanafil for ED treatment, and validated questionnaires were used to assess erectile function and treatment satisfaction. However, the limitations of this study include single-center observational study design, small sample size, and short-term follow-up. Conclusion Avanafil is an effective treatment for ED, and satisfaction rate is high in an outpatient setting. The awareness of identified factors related to patient satisfaction may improve treatment outcomes.

medicine, general & internal,urology & nephrology

What problem does this paper attempt to address?

### Problems the paper attempts to solve

This study aims to evaluate the treatment effect of avanafil in the real - world and patients' satisfaction with the treatment, and explore the factors affecting treatment satisfaction. Specifically, the study mainly focuses on the following two issues:

1. **How effective is avanafil in actual clinical applications?**
- The study measures the treatment effect of avanafil by evaluating patients' erectile function (using the SHIM questionnaire).

2. **How satisfied are outpatients with avanafil treatment?**
- The study evaluates patients' satisfaction with avanafil treatment through questionnaires (including the EDITS questionnaire).

### Research background

- **Avanafil** is a second - generation phosphodiesterase type 5 (PDE5) inhibitor, which has the characteristic of rapid onset (within 15 minutes).
- **Erectile dysfunction (ED)** is a common male sexual dysfunction that affects the quality of life.
- **Insufficient existing data**: Although avanafil has shown good efficacy and tolerability in clinical trials, data in the real - world, especially data on treatment satisfaction, are still lacking.

### Research methods

- **Research design**: This is a phase 4, open - label, cross - sectional, observational study.
- **Research subjects**: A total of 234 ED patients were continuously recruited in the outpatient department from November 2021 to February 2023.
- **Data collection**: At each follow - up (once every 4 weeks), patients completed questionnaires to evaluate the use of avanafil, adverse events during treatment, ED severity and treatment satisfaction.
- **Outcome indicators**:
- Use the SHIM questionnaire to evaluate erectile function.
- Use the EDITS questionnaire to evaluate treatment satisfaction.

### Main results

- **Treatment effect**:
- Avanafil significantly improved the total SHIM score, from 10.2 ± 5.6 at baseline to 17.5 ± 6.2 after treatment (P < 0.001).
- 71.4% of patients had an increase of more than 4 points in the total SHIM score, and 33.1% of patients recovered normal erectile function.

- **Treatment satisfaction**:
- Patients were highly satisfied with avanafil treatment, and 87.5% of patients reported high satisfaction (EDITS index score ≥ 60).
- Factors affecting satisfaction include: being young, having a smaller waist circumference, having a lower low - density lipoprotein (LDL) level, having a shorter duration of ED, having a higher baseline SHIM total score, not having used other PDE5 inhibitors, and having acquired premature ejaculation, etc.

### Conclusions

- **Avanafil shows good effectiveness and safety in actual clinical applications**.
- **Patients are highly satisfied with avanafil treatment**, and are affected by multiple baseline characteristics and erectile function after treatment.
- **Avanafil is an effective option for ED patients who need rapid onset and on - demand treatment**.

### Keywords

- Avanafil; Phosphodiesterase type 5 inhibitor; Erectile dysfunction; Treatment satisfaction.